|
26 Dec 2025 |
CCL Products
|
Consensus Share Price Target
|
954.80 |
1070.50 |
- |
12.12 |
buy
|
|
|
|
|
10 Nov 2025
|
CCL Products
|
Keynote Capitals Ltd
|
954.80
|
1284.00
|
1068.45
(-10.64%)
|
34.48 |
Buy
|
|
|
Quarterly Update Q2FY26
|
|
07 Nov 2025
|
CCL Products
|
Axis Direct
|
954.80
|
1140.00
|
1025.15
(-6.86%)
|
19.40 |
Buy
|
|
|
With a 17% upside from the CMP, we maintain our BUY rating on the stock.
|
|
07 Nov 2025
|
CCL Products
|
IDBI Capital
|
954.80
|
932.00
|
1025.15
(-6.86%)
|
Target met |
Hold
|
|
|
CCL Products Q2FY26 performance was above our expectations. Sales grew 53% YoY to Rs11.3bn, driven by 20+% YoY volume growth and 33% YoY increase in realization due to improved coffee blends and higher prices. Gross margin contracted by 524bps YoY to 34.5%, primarily due to higher input costs. Consequently, EBITDA margin contracted by 107bps YoY to 17.5%, despite operational efficiencies and a favorable product mix. PAT increased by 36% YoY to Rs1,009mn. CCL maintained its volume and EBITDA growth guidance of 1020% and 15-20%, respectively and expects to close FY26 toward the upper end of this range. We value the stock at a PER of 25x FY27E EPS, arriving at a target...
|
|
08 Aug 2025
|
CCL Products
|
Keynote Capitals Ltd
|
954.80
|
1203.00
|
864.35
(10.46%)
|
25.99 |
Buy
|
|
|
Quarterly Update Q1FY26
|
|
07 Aug 2025
|
CCL Products
|
IDBI Capital
|
954.80
|
849.00
|
862.65
(10.68%)
|
Target met |
Hold
|
|
|
CCL Products Q1FY26 profitability was below our expectations. Sales grew 37% YoY to Rs10.7bn, driven by 9-10% YoY volume growth and 27-28% YoY increase in realization due to improved coffee blends. Gross margin contracted by 543bps YoY to 32.6%, driven by higher input cost. Consequently, EBITDA margin contracted by 178bps YoY to 15.1%. EBITDA grew 22% YoY to Rs1.6bn, driven by a favorable product mix in B2B and growth in the B2C category. PAT increased by 1% YoY to Rs724mn. CCL maintained its volume and EBITDA growth guidance of 10-20% and 15-20%, respectively. Management expects some price...
|
|
07 Aug 2025
|
CCL Products
|
Axis Direct
|
954.80
|
970.00
|
862.65
(10.68%)
|
Target met |
Buy
|
|
|
With a 12% upside from the CMP, we maintain our BUY rating on the stock.
|
|
07 May 2025
|
CCL Products
|
Keynote Capitals Ltd
|
954.80
|
1126.00
|
772.60
(23.58%)
|
17.93 |
Buy
|
|
|
Quarterly Update Q4FY25
|
|
07 May 2025
|
CCL Products
|
Axis Direct
|
954.80
|
800.00
|
772.60
(23.58%)
|
Target met |
Buy
|
|
|
With a 15% upside from the CMP, we maintain our BUY rating on the stock
|
|
06 May 2025
|
CCL Products
|
IDBI Capital
|
954.80
|
738.00
|
772.60
(23.58%)
|
Target met |
Hold
|
|
|
|
|
07 Feb 2025
|
CCL Products
|
IDBI Capital
|
954.80
|
698.00
|
654.35
(45.92%)
|
Target met |
Hold
|
|
|
|
|
07 Feb 2025
|
CCL Products
|
Keynote Capitals Ltd
|
954.80
|
1146.00
|
654.35
(45.92%)
|
20.03 |
Buy
|
|
|
Quarterly Update Q3FY25
|
|
07 Feb 2025
|
CCL Products
|
Axis Direct
|
954.80
|
730.00
|
654.35
(45.92%)
|
Target met |
Buy
|
|
|
With a 13% upside from the CMP, we maintain our BUY rating on the stock.
|
|
28 Jan 2025
|
CCL Products
|
CD Equisearch
|
954.80
|
681.00
|
599.45
(59.28%)
|
Target met |
Accumulate
|
|
|
|
|
11 Nov 2024
|
CCL Products
|
BP Wealth
|
954.80
|
|
713.05
(33.90%)
|
|
Results Update
|
|
|
|
|
11 Nov 2024
|
CCL Products
|
Keynote Capitals Ltd
|
954.80
|
1222.00
|
713.05
(33.90%)
|
|
Buy
|
|
|
Quarterly Update Q2FY25
|
|
07 Nov 2024
|
CCL Products
|
IDBI Capital
|
954.80
|
734.00
|
691.70
(38.04%)
|
Target met |
Hold
|
|
|
|
|
07 Nov 2024
|
CCL Products
|
Axis Direct
|
954.80
|
820.00
|
701.40
(36.13%)
|
Target met |
Buy
|
|
|
With a 14% upside from the CMP, we maintain our BUY rating on the stock.
|
|
09 Sep 2024
|
CCL Products
|
Keynote Capitals Ltd
|
954.80
|
1221.00
|
747.05
(27.81%)
|
|
Buy
|
|
|
Initiating Coverage Report
|
|
09 Aug 2024
|
CCL Products
|
Axis Direct
|
954.80
|
760.00
|
659.85
(44.70%)
|
Target met |
Buy
|
|
|
With a 15% upside from the CMP, we maintain our BUY rating on the stock.
|
|
14 May 2024
|
CCL Products
|
Axis Direct
|
954.80
|
670.00
|
563.40
(69.47%)
|
Target met |
Buy
|
|
|
With a 17% upside from the CMP, we maintain our BUY rating on the stock.
|